Safety Profile of Sacituzumab Govitecan–Based Treatment in Frontline TNBC

As ADCs enter the frontline setting, understanding their safety profiles is essential. The panelists examine data showing that sacituzumab govitecan’s adverse events are largely manageable with proper monitoring. Common toxicities include neutropenia, diarrhea, fatigue, and nausea—consistent with its mechanism of delivering SN-38, the active metabolite of irinotecan. They stress the importance of early recognition and intervention, including growth factor support and dose modifications when needed. In clinical practice, patient education and proactive management of gastrointestinal and hematologic side effects can maintain treatment adherence and quality of life. The panel concludes that with proper management, the safety profile of sacituzumab govitecan is acceptable and compares favorably to traditional chemotherapy regimens.